Amylin Pharmaceuticals Inc  (AMLN) Trade Now »     Rate AMLN  -  Discuss AMLN  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

AMLN: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

A Calendar of Expected Clinical Trial Results AMLN

73%

+11.24% in 315 days A Calendar of Expected Clinical Trial Results <> The accompanying table [click to enlarge] includes 58 entries of expected clinical trial results in addition to pending FDA applications for new product approvals + a list of companies which will be required to re-submit their applications due to complete response letters from the agency. See my recent article on 20 emerging healthcare stocks to watch in 2009 for more details on some of the companies included in the accompanying calendar, in addition to the following companies with near-term catalysts in... Continue reading »

Updated FDA Calendar AMLN

73%

+15.03% in 29 days (closed on 01/11/09) Updated FDA Calendar: Buying Cypress Bioscience <> The accompanying table [click to enlarge] includes a weekly update of 71 expected FDA decision dates as part of the ETF Innovators [ETFI] New Drug Regulatory Decision Catalyst Index. Since my article last week , the following action has taken place at FDA: 1.) Pain Therapeutics (PTIE) & King Pharma (KG) lost 21% and 7%, respectively, today after receiving a complete response letter from the FDA for their abuse-resistant form of controlled-release oxycodone, which is designed to deter the abuse and diver... Continue reading »

Bullish on AMLN ... AMLN

N/A

-61.40% in 465 days AMLN is getting streangth from from its last successful second quarter where sale of product increased 20% wrote in a research note Analyst Shah from Stock Mania. Continue reading »

Uptrend for Amylin? AMLN

63%

-58.51% in 472 days Broke through resistance, following a gap up, on the way to testing the 34 resistance again? Recent buyers all within the 28-29 zone so there is a good support zone there. Technical idea, follow the trend line. Continue reading »

Amylin Pharmaceuticals Inc. AMLN

62%

-51.00% in 517 days Amylin and Mallinckrodt amended their manufacturing agreement dated October 1, 2003, pursuant to which Mallinckrodt manufactures and supplies to Amylin bulk exenatide, the active ingredient in BYETTA injection. Under the terms of the Amendment, the termination date of agreement has been extended for a period of four years to September 30, 2012. Continue reading »

From the Blogosphere

Good News for Alkermes’ Pipeline – Analyst Blog

38%

Recently, Alkermes Inc. (ALKS) announced that its drug Vivitrol, which is indicated for the treatment of alcohol dependence, also helped opioid addicts stay away from drugs. Data from the six-month late-stage trial (n=250) demonstrated that subjects injected with Vivitrol (naltrexone for extended-release injectable suspension) once a month were more likely to pass a urine test compared to recipients of a placebo injection. Furthermore, subjects reported a lower craving for drugs, and half the subjects came clean in at least 90% of their drug tests.   The subjects were addicted to opioid dr... Continue reading »

Zacks Analyst Blog Highlights: Clorox Company, Arena Pharmaceuticals, Vivus Inc., Orexigen Therapeutics and Amylin Pharmaceuticals – Press Releases

38%

For Immediate Release Chicago, IL – November 3, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Clorox Company (CLX), Arena Pharmaceuticals (ARNA), Vivus Inc. (VVUS), Orexigen Therapeutics (OREX) and Amylin Pharmaceuticals (AMLN). Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513 <><>Here are highlights from Monday’s An<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>< />< />< />< /><><><><>< /><><>< /><>< /><>< />< />... Continue reading »

Amylin Strikes First on Obesity – Analyst Blog

38%

Almost all of the news in the obesity race has been made recently by three small biotech companies -- Arena Pharmaceuticals (ARNA), Vivus Inc. (VVUS) and Orexigen Therapeutics (OREX), but yesterday it was mid-cap Amylin Pharmaceuticals (AMLN) that signed the first partnership in what was originally perceived to be a three-horse race.  Amylin and Takeda Pharmaceutical Company Limited entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pramlintide/metreleptin and davalintide, two phase II compounds for the treatment of obesi... Continue reading »

Trading Radar for 7/21: Apple (AAPL), Merck (MRK), Coca-Cola (KO), Cat (CAT), Freeport-McMoRan (FCX), Yahoo! (YHOO), State Street (STT), BlackRock (BLK), Amylin (AMLN), Starbucks (SBUX) Report

The Trading Radar highlights key earnings and economic announcements for tomorrow's trading session:<u>Before Market Opens:</u>Earnings:AK Steel (NYSE: AKS) - consensus loss $0.51BlackRock (NYSE: BLK) - consensus EPS $1.58Caterpillar (NYSE: CAT) - consensus EPS $0.22Comerica (NYSE: CMA) - consensus loss $0.44Continental Airlines (NYSE: CAL) - consensus loss $1.36DuPont (NYSE: DD) - consensus EPS $0.53Elan (NYSE: ELN) - consensus loss $0.15Forest Labs (NYSE: FRX) - consensus EPS $0.82Freeport-McMoRan (NYSE: FCX) - consensus EPS $0.69Kinetic Concepts (NYSE: KCI) - consensus EPS $0.95LaBranche... Continue reading »

Trading Radar for 7/21: Apple (AAPL), Merck (MRK), Coca-Cola (KO), Cat (CAT), Freeport-McMoRan (FCX), Yahoo! (YHOO), State Street (STT), BlackRock (BLK), Amylin (AMLN), Starbucks (SBUX) Report

The Trading Radar highlights key earnings and economic announcements for tomorrow's trading session:<u>Before Market Opens:</u>Earnings:AK Steel (NYSE: AKS) - consensus loss $0.51BlackRock (NYSE: BLK) - consensus EPS $1.58Caterpillar (NYSE: CAT) - consensus EPS $0.22Comerica (NYSE: CMA) - consensus loss $0.44Continental Airlines (NYSE: CAL) - consensus loss $1.36DuPont (NYSE: DD) - consensus EPS $0.53Elan (NYSE: ELN) - consensus loss $0.15Forest Labs (NYSE: FRX) - consensus EPS $0.82Freeport-McMoRan (NYSE: FCX) - consensus EPS $0.69Kinetic Concepts (NYSE: KCI) - consensus EPS $0.95LaBranche... Continue reading »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.